Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $215.00 short call and a strike $220.00 long call offers a potential 14.42% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $215.00 by expiration. The full premium credit of $0.63 would be kept by the premium seller. The risk of $4.37 would be incurred if the stock rose above the $220.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 36.48 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen Stock Rises 3%
Mon, 02 Mar 2020 11:56:00 +0000
Investing.com – Amgen (NASDAQ:AMGN) Stock rose by 3.03% to trade at $205.82 by 11:54 (16:54 GMT) on Monday on the NASDAQ exchange.
Why Is Amgen (AMGN) Down 11.7% Since Last Earnings Report?
Sat, 29 Feb 2020 16:31:04 +0000
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen Stock Falls 4%
Fri, 28 Feb 2020 14:11:00 +0000
Investing.com – Amgen (NASDAQ:AMGN) Stock fell by 3.69% to trade at $195.75 by 14:09 (19:09 GMT) on Friday on the NASDAQ exchange.
Amgen To Present At The Cowen 40th Annual Healthcare Conference
Fri, 28 Feb 2020 01:00:00 +0000
Amgen (NASDAQ:AMGN) will present at the Cowen 40th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 2, 2020 in Boston. Peter H. Griffith, executive vice president and chief financial officer, and Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
Biohaven drug wins U.S. FDA approval for use in relieving migraine headaches
Thu, 27 Feb 2020 23:11:41 +0000
The U.S. Food and Drug Administration on Thursday approved Biohaven Pharmaceutical Holding Co Ltd's oral pill for relieving pain after the onset of migraine headaches, the drug developer said. Nurtec ODT, chemically known as rimegepant, belongs to an emerging class of migraine treatments called calcitonin gene-related peptide (CGRP) inhibitors and directly competes with Allergan Plc's Ubrelvy, which became the first oral CGRP to be approved for acute migraine in December. A single oral dose of the 75 mg tablet can provide fast pain relief, return patients to normal function within an hour, and remain effective for up to 48 hours for many patients, the company said.
Also on Market Tamer…
Follow Us on Facebook